laitimes

Haite Bio: Detecting micro residual diseases is the future research and development direction of Beijing Shadong will not affect the CPT registration application

Tonghuashun (300033) Financial Research Center, June 7, some investors asked Haite Bio (300683), Cde's official website on the public solicitation of "technical guidelines for the detection of micro residual diseases in clinical trials of multiple bone marrow cancer drugs" Whether the CPT registration application has an impact, is there a conflict? What if there is an impact to prepare?

The company replied, Hello! Thank you for your interest in the company. The indications for CPT phase III clinical research are relapsed or refractory multiple myeloma, and the detection of micro residual diseases is the future research and development direction of Beijing Shadong, which will not affect the application for CPT registration. Thank you.

This article originated from the Flush Financial Research Center

Read on